GlassScriptPhysician profile
Basiem W Barsoum
NPI 1104099456
$2,001.47
in general payments reported to CMS, 2019-2025
24 companies · $799 in 2025
The $799 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.04 · 2021: $116 · 2022: $151 · 2023: $154 · 2024: $729 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argon Medical Devices, INC. | $272.33 | 2025 | Clot Management |
| Abbott Laboratories | $182.92 | 2021-2025 | Jot Dx |
| Stryker Corporation | $180.21 | 2025 | Flowtriever |
| Kestra Medical Technology Services, INC. | $178.77 | 2024 | Assure Wcd |
| Medtronic, INC. | $163.76 | 2024-2025 | Symplicity G3 |
| Actelion Pharmaceuticals US, INC. | $135.59 | 2025 | Uptravi |
| Abiomed | $131.67 | 2019-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.27 | 2022-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $84.56 | 2023-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $77.80 | 2023-2025 | |
| Boston Scientific Corporation | $71.51 | 2023-2025 | Ekosonic, Watchman Access System |
| Angiodynamics, INC. | $57.81 | 2022-2024 | Alphavac |
| Kiniksa Pharmaceuticals, LTD. | $49.49 | 2023 | Arcalyst |
| Biotronik INC. | $48.02 | 2024 | Biomonitor |
| Amgen INC. | $42.68 | 2022-2024 | Repatha |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $37.78 | 2024 | |
| Cvrx, INC. | $35.73 | 2024-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $29.76 | 2024 | Xarelto |
| Penumbra, INC. | $28.21 | 2025 | Indigo System |
| Alnylam Pharmaceuticals INC. | $21.60 | 2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $20.37 | 2024 | Farxiga |
| Resmed Corp | $17.19 | 2023 | |
| Philips North America LLC | $16.96 | 2019 | |
| Pfizer INC. | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basiem Barsoum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.